hydrocortisone topical (Rx, OTC)

Brand and Other Names:Westcort, Locoid, more...Aquanil, Calmurid Cream, Cetacort, Claritin Skin Itch Relief, Coraz, CortaGel, Cortaid, Cortate, Cortisone-10 Poison Ivy Relief Pads, Cortisone-10 Quick Shot, Cortizone, Cortoderm, Dermacort, Dermazene Cream, DermiCort, Emo Cort, Hyderm, Hydrocort, HydroSKIN, HydroVal, Hytone, LactiCare, AlaCort, Locoid Lipocream, Massengill, Neosporin Eczema Essentials Anti-Itch Cream, Nutracort, Pediaderm HC, Penecort, Preparation H Anti-Itch Cream, Prevex HC, Proctocort, Proctocream, Sarna HC, Sarnol, Texacort, Timodine, Uniroid HC, AlaScalpt
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

topical cream

  • 0.1%
  • 0.2%
  • 0.5%
  • 1%
  • 2.5%

topical lotion

  • 0.1%
  • 1%
  • 2%
  • 2.5%

topical gel

  • 1%
  • 10%

topical solution

  • 1%
  • 2.5%

topical ointment

  • 0.2%
  • 0.5%
  • 1%
  • 2.5%
more...

Atopic Dermatitis

Apply thin film to affected area BID

Corticosteroid-responsive Dermatoses

Relief of inflammatory and pruritic manifestations

Hydrocortisone base: q6-12hr

Hydrocortisone acetate: q6-12hr

Hydrocortisone butyrate: q8-12hr

Hydrocortisone valerate: q8-12hr

Dosage Forms & Strengths

topical cream

  • 0.1%
  • 0.2%
  • 0.5%
  • 1%
  • 2.5%

topical lotion

  • 0.5%
  • 1%
  • 2%
  • 2.5%

topical gel

  • 1%

topical solution

  • 1%
  • 2.5%

topical ointment

  • 0.2%
  • 0.5%
  • 1%
  • 2.5%
more...

Corticosteroid-responsive Dermatoses

Relief of inflammatory and pruritic manifestations

Infants, children, and adolescents; products for OTC use are not labeled for use in children <2 years

Hydrocortisone base: q6-12hr

Hydrocortisone acetate: q6-12hr

Hydrocortisone butyrate: q8-12hr

Dosing considerations

  • Limit to the minimum amount necessary for therapeutic efficacy

Atopic Dermatitis

<3 months: Safety and efficacy not established

>3 months: Apply film to affected area q12hr

Next:

Adverse Effects

Frequency Not Defined

Skin atrophy

Striae

Acneform lesions

Perioral dermatitis

Folliculitis

Itching

Pigmentation changes

HPA suppression (with higher potency used >2 wk)

Previous
Next:

Warnings

Contraindications

Underlying infection

Hypersensitivity

Ophthalmic use

Treatment of diaper dermatitis

Cautions

Chronic topical corticosteroid therapy may interfere with growth and development in children

Use lower potency in children; may absorb proportionally larger amounts after topical application and may cause systemic effects

Occlussive dressings, prolonged use, application to large surface areas, or application to denuded skin, may increase percutaneous absorption, which may result in cushing syndrome, glycosuria, and hyperglycemia

Prolonged use may increase risk of Kaposi's sarcoma

Prolonged use may increase risk of secondary infection, may mask acute infection, limit response to vaccines, and prolong or exacerbate viral infections; avoid exposure to measles or chickenpox while receiving therapy; not for the treatment of ocular herpes simplex, cerebral malaria, fungal infections, or viral hepatitis; observe patients with latent tuberculosis closely; restric use in active tuberculosis

Acute myopathy reported with high dose corticosteroids, especially patients with neuromuscular transmission disorders

Psychiatric disturbances including euphoria, insomnia, mood swings, and personality changes reported with corticosteroid use

Allergic contact dermatitis may occur; diagnosed as failure to heal rather than exacerbation; discontinue therapy and treat appropriately if it occurs

May suppress hypothalamic-pituitary-adrenal axis, especially in patients receiving high doses for prolonged periods of time and younger children, which may result in adrenal crisis

Anaphylactoid reactions reported in patients receiving corticosteroids

Local desensitization (irritation, redness) reported; discontinue if it occurs

Use caution in patients with diabetes, cardiovascular disease, hepatic impairment, myocardial infarction, myasthenia gravis, osteoporosis, ocular disease, renal impairment, or thyroid disease

Previous
Next:

Pregnancy & Lactation

Pregnancy

There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids; corticosteroids generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels; topical corticosteroids should be used during pregnancy only if potential benefits justify potential risk to fetus; should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time

Lactation

Not know whether topical administration could result in sufficient systemic absorption to produce detectable quantities in breast milk; systemically administered corticosteroids are secreted into breast milk in quantitis not likely to have deleterious effect on infant; nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman

Pregnancy Categories

A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA:Information not available.

more...
Previous
Next:

Pharmacology

Mechanism of Action

Decreases inflammation by stabilizing leukocyte lysosomal membranes, preventing release of destructive acid hydrolases from leukocytes

Inhibits macrophage accumulation in inflamed areas

Reduces leukocyte adhesion to capillary endothelium

Reduces capillary wall permeability and edema formation

Decreases complement components and antagonizes histamine activity and release of kinin from substrates

Reduces fibroblast proliferation, collagen deposition, and subsequent scar tissue formation

Absorption

Percutaneous; extent of absorption in dependent on formulation, epidermal integrity (intact vs abrated), and the use of occlusive dressings

Previous
Next:

Images

Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous